Introduction
U ncontrolled hemorrhage is the leading cause of death during the prehospital period in both military combat and civilian trauma cases. [1] [2] [3] Immediate intervention by an on-scene first responder or by the wounded themselves is one of the most effective methods of limiting patient mortality. 4 Interestingly, the methods of controlling bleeding in the prehospital period have not changed significantly in the last 2,000 years. 5 Although bleeding from extremity injuries can usually be controlled by direct pressure or, if severe, by the application of a tourniquet, presently little can be done to control bleeding from complex chest, abdomen, or pelvis wounds. This was certainly the case during military operations in Somalia and Afghanistan in which penetrating wounds to the groin and pelvic regions caused significant mortality among American military personnel. 6 To reduce the mortality from these types of wounds as well as the time required to control severe bleeding, the U.S. Army (USA) and Marine Corp (USMC) are investigating a number of recently developed hemorrhage control technologies. The military is seeking a hemostatic device that is effective, inexpensive, easy to transport, and easy to apply. In this article, we review the hemostatic dressings and tourniquets examined and used by the USA and USMC and report on their effectiveness in both laboratory trials and field situations during Operation Iraqi Freedom.
Fibrin
Fibrin glues, foams, and tissue-adhesive bandages are a group of products that lead to the formation of a thrombus or clot at the site of application. These products contain extremely high concentrations of fibrinogen, thrombin, and sometimes additional components such as calcium, factor XIII, or even antifibrinolytics, all of which work to mimic the final stages of the blood coagulation cascade. Although these components are naturally present in every wound, these products supply the clotting cofactors in a much higher concentration than is available physiologically, leading to more rapid clot formation. 7 The medical use of fibrin to assist in clotting is not an entirely new concept. 8, 9 The development and application of fibrin in a military setting began in World War II:
When thrombin first became available, Lt. Edgar A. Bering, Jr., MC, USN and Dr. Bailey had applied it in solution to bleeding points in several cranial and spinal operations. It did no harm. . . but its effect was entirely transient. Lieutenant Bering then conceived the idea of using fibrinogen, converted into fibrin foam, as a matrix. . . The first applications of fibrin foam were made in cases in which bleeding was difficult to control and the application of muscle was not feasible. The hemostatic effect was evident. . . It was agreed that the material was of extraordinary value as a hemostatic agent in neurosurgery. It had proved of great value in hemophiliacs, in controlling bleeding from traumatic lacerations, and in maintaining hemostasis during minor surgical procedures such as tooth extractions. 10 Since the 1970s, fibrin glues and sealants produced from either human or bovine donors have been used extensively in fields as varied as abdominal surgery, organ resection, cosmetic surgery, and cardiovascular surgery. [11] [12] [13] [14] [15] [16] Initially, there was some fear of disease transmission by fibrin products, but advances in production and purification have virtually eliminated these risks. 16 The chief difficulty now is that liquid fibrin products have a short shelf life and need to be mixed each time they are required for use. This requires added time and extensive laboratory and blood bank support, limiting the usefulness of these products in first-response (field) situations. Because of the limitations of liquid preparations, current investigative efforts have focused on the production of dry fibrin bandages for use in hemorrhage control.
In multiple animal studies, fibrin bandages have proven to significantly decrease blood loss during hemorrhage. Two of these studies were large-animal surgical models (Yorkshire swine), both of which demonstrated that the fibrin bandage treatment achieved faster blood clotting and resulted in less blood loss and a more normal blood pressure profile than a standard gauze pressure bandage treatment, which consists of applying manual pressure to a wound using a gauze pad (Table  I) . 17, 18 A third study was a large-animal ballistic wounding model (Angora goats) which showed that the fibrin dressing was superior to the standard pressure bandage treatment in controlling hemorrhage from gunshot wounds inflicted by a 0.308 caliber high-velocity bullet. In equivalent injuries to the experimental subjects, blood loss was significantly lower in the fibrin bandage treatment group than in the control group (124 Ϯ 64 mL vs. 377 Ϯ 64 mL, p ϭ 0.01; p values are written as reported in the original journal article) and the mean arterial pressure was also maintained higher in the fibrin bandage group (95.0 Ϯ 4.7 mm Hg vs. 70.0 Ϯ 5.0 mm Hg, p ϭ 0.01; p values are written as reported in the original journal article). 19 A fourth study which compared 10 different hemostatic dressings in an animal surgery model demonstrated that fibrin dressings were as effective in stopping hemorrhage in the surgical repair of a vascular wound as were sutures, with all animals in the fibrin and suture groups surviving the observation period with minimal bleeding in the postocclusion period (Ͻ37 mL in each group). 20 Numerous other studies have also demonstrated the efficacy of the dry fibrin bandage in various other surgical uses. [21] [22] [23] [24] [25] Current literature supports effectiveness of the dry fibrin bandage; unfortunately, the bandage is very expensive (approximately $1,000 per 4-inch square) and it has not yet been approved for routine use by the Food and Drug Administration (FDA). 22 Research is being directed at augmenting the fibrin to enhance its effectiveness and reduce the amount needed for each bandage, thus lowering the cost. However, this is still experimental and has so far only showed limited promise. 26, 27 The bandage itself is also brittle and is subject to damage in rough use, limiting both its ability to be applied by a less experienced provider and its effectiveness in the military field setting. It is also difficult to insert into deep wounds because of its brittleness, further limiting its utility for military applications. 28 
Microporous Polysaccharide Hemosphere
Another approach to improving hemostasis has been to apply substances that decrease the local tissue fluid and therefore increase the relative concentration of clotting factors in the wound without actually adding exogenous clotting factors such as fibrin. A small number of these types of hemostatic agents have been marketed over the past few years and have received FDA approval. The microporous polysaccharide hemosphere compound is an example of one of these recently developed agents. The microporous polysaccharide hemosphere made for first responders is sold as TraumaDEX (Medafor, Inc., Minneapolis, Minnesota) and comes in a powder that is poured into open wounds (Fig. 1) . It assists in clotting by absorbing water and low molecular weight products from the blood, allowing clotting factors and platelets to become more concentrated. 29 TraumaDEX is relatively safe and simple because it is bioinert, contains no human proteins, has an extended shelf life, and can be applied in a one-step process. 30 Studies suggest that TraumaDEX is effective in accelerating hemostasis time in animal and human wounds. 31 However, a recent study has shown that TraumaDEX may be ineffective in clotting severe external hemorrhages. Alam et al. 32 studied TraumaDEX and other hemostatic substances in a lethal Yorkshire swine animal model created by transecting the femoral artery and vein. In that study, swine were separated into five groups with each group receiving one of five treatments: (1) no dressing, (2) standard dressing (consisting of an 8 ϫ 10-inch absorbent pad and elastic bandage [Cinch Tight, H&H Associates, Bena, VA]), (3) standard dressing and Rapid Deployment Hemostat bandage (Marine Polymer Technologies, Danvers, MA), (4) standard dressing and QuikClot (Z-Medica, Newington, CT), and (5) standard dressing and TraumaDEX. As compared with standard treatment, the TraumaDEX dressing did not cause a statistically significant decrease in mortality. 32 Thus, the powder appears to be effective in accelerating hemostasis time in minor to moderate wounds, 31 but not in severe hemorrhaging wounds. 32 Because of these results, neither the USA nor the USMC chose to use TraumaDEX to treat their wounded during Operation Iraqi Freedom.
Mineral Zeolite
Another recently developed hemostatic agent that increases the clotting factor concentration in the wound by adsorbing liquid is the mineral zeolite powder QuikClot (Fig. 2) . The pow- der is poured into the wound and increases hemostasis by adsorbing water and concentrating clotting factors in the blood. QuikClot has properties similar to those of TraumaDEX in that it is bio-inert, nonallergenic, sterile, a one-step application, and inexpensive ($20 per packet, average wholesale price).
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Results from the study performed by Alam et al. 32 demonstrated that QuikClot effectively increased survival and decreased hemorrhage in a lethal groin injury model as compared to standard methods of hemorrhage control. In that animal study, the control group, which was treated with no dressing, had an 83% mortality, the group treated with only the standard dressing (which consisted of an 8 ϫ 10-inch absorbent pad and elastic bandage) had a 33.4% mortality, and the group treated with the standard dressing and QuikClot had a 0% mortality. In addition, the group treated with both the standard dressing and QuikClot had the lowest volume of blood lost; however, this was not statistically significant compared with the control group. 32 A unique side effect of QuikClot is that the adsorption of water causes an exothermic reaction. The temperature quickly rises after application to between 42°C and 44°C. 32 This temperature rise is transient, lasting only a few minutes. Local tissue burn injury has been shown to occur in a number of animal models; however, the investigators concluded that the risk of tissue damage was far outweighed by the benefit of increased survival when QuikClot is used to treat an otherwise uncontrollable exsanguinating hemorrhage. 34 At the request of the USMC, a multiservice panel was convened at the Uniformed Services University in February 2003 to review the results of the study by Alam et al. 32 and to make recommendations regarding the safe use of QuikClot. 34 Some of these recommendations were that the product should be: used only where there is a life-threatening hemorrhage; used only on external wounds; used only after standard methods have failed to control hemorrhage; issued only to personnel who are adequately trained to apply the product; and reported each time a packet is used to ensure that the product is not used for less severe injuries. 34 After the recommendations by the panel were reviewed, QuikClot was issued to U.S. Navy corpsmen to be used in treating casualties during combat operations in Iraq. Comments from a USMC after-action report showed that QuikClot might have not been as effective as the USMC had hoped. Some of the comments were:
-Wounded Iraqi civilian. Shot near brachial artery. QuikClot was applied per the instructions. The substance dried but was flaking off. Standard direct pressure applied by corpsman proved more effective on the patient. -Iraqi civilian shot in back with punctured spine. QuikClot applied to severe bleeding. Pressure from bleeding sprayed QuikClot away. According to LT Webb, "QuikClot was everywhere but the wound." -Iraqi civilian, female, shot in femoral artery. She suffered severe arterial bleeding. Patient bled out. QuikClot unable to be applied effectively due to pressure of blood flow from wound. Patient died. -An LAR Marine was shot in the femoral artery. QuikClot was applied to the heavily bleeding wound. The pressure from the blood soon caused the QuikClot to be pushed out of the wound and rendered ineffective. A tourniquet was applied instead. The patient died. 35 Although comments from the USMC report suggest that QuikClot was ineffective in the treatment of these specific wounds, the USMC comments do not reflect every individual application of QuikClot in Operation Iraq Freedom. Furthermore, in some of the above instances, QuikClot was not used according to the manufacturer's directions or USMC guidelines. On the other hand, perhaps QuikClot was ineffective in the above instances because combat setting wounds are different than laboratory-simulated wounds. The lethal groin injury model that Alam et al. 32 used on swine could have had blood pooling in the inguinal cavity, causing the blood to flow slower and to be more apt to clot. However, a brachial artery transection in a human might be different because of the high flow and absence of pooling at the site of application. Consequently, researchers cannot draw a definite conclusion as to its effectiveness in the overall combat setting based solely on these anecdotal reports.
Poly-N-Acetylglucosamine
Chitin (poly-N-acetylglucosamine) is a polysaccharide biopolymer produced naturally by algae through fermentation. Both chitin and its deacetylated form, chitosan, have been shown to be effective hemostatic agents. [36] [37] [38] [39] The exact mechanism of action is still under study but is postulated to be via vasoconstriction and the rapid mobilization of red blood cells, clotting factors, and platelets to the site of the injury. 40 The military is specifically interested in poly-N-acetylglucosamine devices as hemostatic agents because they have stable shelf lives, are easy to use, and are relatively inexpensive.
Although chitin has been shown to be effective in the treatment of minor wounds, 36, 37 it is controversial if the product is effective in the treatment of more severe wounds. In a surface splenic laceration animal model, the chitin dressing (made by Marine Polymer Technologies, Danvers, Massachusetts) was proven to provide significantly faster coagulation than fibrin glues (22.9 seconds vs. 172.9 seconds, p Ͻ 0.01; p values are written as reported in the original article). 41 However, in a recent study by Pusateri et al., 42 a chitin dressing (Marine Polymer Technologies) showed no significant advantage over the standard 10.2 ϫ 10.2-cm gauze sponge (Nu Gauze general-use sponges, Johnson & Johnson Medical, Inc., Arlington, Texas) in stopping bleeding from a severe large venous hemorrhage and hepatic injury in swine.
Chitosan has been shown to be more efficacious than chitin in controlling severe hemorrhage from simulated combat wounds. In another study by Pusateri et al., 43 chitosan was demonstrated to reduce blood loss (264 mL vs. 2,879 mL, p Ͻ 0.01; p values are written as reported in the original article) and increase survival (87.5% vs. 28.6%, p ϭ 0.04; p values are written as reported in the original article) as compared with gauze control groups in a severe hepatic injury in swine. The USA has issued its Special Forces Units specific chitosan dressings manufactured by HemCon Hemorrhage Control Technologies (Lake Oswego, Oregon) (Fig. 3) . Anecdotal case reports from Operation Iraqi Freedom about the efficacy of HemCon dressings have been positive, including an isolated report of a gunshot wound to the right foot that suggested superiority of a HemCon dressing with direct pressure over the standard medical dressing. American medical personnel had primarily treated the wound with a standard bandage, but soon after the bandage was soaked with blood. The bandage was removed and a HemCon dressing was applied with 4 minutes of direct pressure. After the pressure on the dressing was removed, the medic noted that hemorrhage control had been achieved (Robert Miller, personal communication).
Microporous Hydrogel-Forming Polyacrylamide
The BioHemostat (Hemodyne, Richmond, Virginia) is part pressure dressing and part hemostatic dressing. When inserted into a wound, the BioHemostat functions by absorbing fluid and expanding to occlude the wound and create backpressure to stop bleeding. The device consists of two components, a liquid absorbing core attached to a traditional bandage. 44 The core is composed of a microporous hydrogel-forming polyacrylamide that has the potential for rapid expansion. 45 According to Carr et al., 45 the material has the capacity to absorb 1,400 times its weight. The core's outer shell is composed of an elastomeric polymer, ethylene-vinyl acetate copolymer that can be treated with hemostatic agents, antibiotics, and analgesics. 45 Once applied, the dressing will remain until patient arrives at a facility for definitive care. The manufacturer asserts that the BioHemostat has the potential to stop arterial hemorrhaging while also saving the limb from ischemic damage and amputation. This dressing concept is ideal for far-forward operators because of its small size, simplicity, and low monitoring requirements once inserted. No data are available to assess BioHemostat's efficacy in a combat setting and further research should be performed.
Conclusion
Although the literature on new techniques for bleeding control and clotting is extremely limited, we have reviewed current publications as well as anecdotal data from unpublished military reports coming from Operation Iraqi Freedom. Although there is not yet a single hemorrhage control mechanism that will be universally effective, there are a number of products that show promise. One approach is to increase the supply of clotting factors, such as fibrin, to the wound to induce rapid hemostasis. Multiple studies demonstrated that the dry fibrin bandage is effective at enhancing clot formation in hemorrhage situations. Unfortunately, the bandage itself is brittle, making it difficult to insert into deep wounds and subject to being fractured when transported by combat medical personnel. The fibrin bandage is also not yet approved by the FDA because of concern about its production from either human or bovine plasma.
Another approach to hemorrhage control is to add a substance to the wound that increases the concentration of local clotting factors. The recently developed hemostatic agents that fall into this category are microporous polysaccharide hemosphere (TraumaDEX), mineral zeolite (QuikClot), and poly-Nacetylglucosamine (HemCon). All three types of products are relatively inexpensive, easy to use, and easy to apply. Trauma-DEX appears to be effective in treating minor to moderate wounds 31 but is less effective in treating severe external hemorrhage. 32 QuikClot, on the other hand, demonstrated efficacy in treating severe external hemorrhages in the laboratory, but has been initially reported as less efficient when used to treat the wounded in Iraq. 35 There is anecdotal evidence from Operation Iraqi Freedom that HemCon is effective (Robert Miller, personal communication), but more data about the agent's performance in a combat setting are needed. None of the hemostatic products discussed herein have anything other than anecdotal data supporting their effectiveness in combat settings when applied by combat medical personnel; thus, more research needs to be performed to draw definite conclusions.
Finally, the combination pressure/hemostatic dressing BioHemostat may provide the hemorrhage control of traditional pressure bandages without inducing necrosis of the distal limb and therefore worsening the tissue injury. However, no research yet published has tested the efficacy of this product on combat wounds.
Uncontrolled hemorrhage is the leading cause of death during the prehospital period in combat. [1] [2] [3] Immediate hemorrhage control by an on-scene first responder is the most effective method of limiting patient mortality. A hemorrhage control device that is effective, inexpensive, easy to transport, and easy to apply may drastically reduce patient mortality on the battlefield.
